Mode
Text Size
Log in / Sign up
Phase 2 N=40

A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration

Early Lumbar Disc Degeneration

Enrolled (actual)
40
Serious AEs
12.5%
Results posted
Jan 2016
Primary outcome: Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 2 participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Intradiscal rhGDF-5 (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
DePuy Spine
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Neurological Assessment for Motor Function and Reflexes/Sensory
0; 2
PRIMARY
Treatment Emergent Adverse Events- Relationship to Study Drug
2; 1
SECONDARY
Change in Function Assessed by Oswestry Disability Index Change at 12 Months From Baseline
-13.0; -18.1
SECONDARY
Change in Pain Visual Analog Scale (VAS) at 12 Months From Baseline.
-2.66; -3.80
SECONDARY
Change in Physical Component Summary of Quality of Life Measure Assessed by Short-Form 36 at 12 Months From Baseline.
11.18; 10.00

Summary

Study to show the safety, tolerability and preliminary effectiveness of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration.

Eligibility Criteria

Inclusion Criteria

  • Persistent low back pain with at least 3 months of non-surgical therapy at one or two suspected symptomatic lumbar levels (L3/L4 to L5/S1)

a. The recruiting physician will use their standard clinical and radiological practice to determine the one/two disc level(s) be treated, i.e., but not limited to a combination of MRI, CT and/or Technetium bone scans, functional x-rays, input from a spinal injection program (targeting facet joints and/or epidural space) and discography (a discogram performed within 12 months of the anticipated study treatment date is acceptable, as long as the subject has not had an accident or re-injury).

  • Oswestry Disability Index (ODI) for low back pain of 30 or greater
  • Low Back Pain score greater than or equal to 4 cm as measured by Visual Analog Scale (VAS) at Visit 1 Baseline
  • Male or Female 18 years of age or older

Exclusion Criteria

  • Persons unable to have an MRI
  • Abnormal neurological exam at baseline (e.g., chronic radiculopathy)
  • Persons with neurological or radiographic evidence of active radicular pain due to anatomical compression such as stenosis or disc herniation (persons with somatic referred pain are allowed)
  • Suspected symptomatic facet joints and/or severe facet joint degeneration at the index level(s) or adjacent segments
  • Suspected symptomatic sacro-iliac joint
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01158924). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search